The first new class of migraine drugs in decades won FDA approval last year. But the companies who commercialized these new therapies and their potential competitors are already planning new, more convenient versions, taken as pills instead of injectoins just below the skin, and they will present key data in the next few days at the annual meeting of the American Academy of Neurology in Philadelphia.
The new class of migraine drugs are called calcitonin gene-related peptide (CGRP) inhibitors, named for a protein associated with the development of migraine pain. By blocking CGRP, the drugs are meant to abort migraine… Read more »
UNDERWRITERS AND PARTNERS